Establishing a model predicting Gleason grade group upgrading in prostate cancer
Translational Andrology and Urology · 2024-08 · 13 (8) · 1378-1387
DOI: 10.21037/tau-24-155 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Andrology and Urology, 2024-08. Verfasst von Jian Chen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Institute of Surgery Research, Daping Hospital, Army Medical University, Chongqing, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Institute of Surgery Research, Daping Hospital, Army Medical University, Chongqing, China.
- Department of Pathology, Institute of Surgery Research, Daping Hospital, Army Medical University, Chongqing, China.
- Department of Bio-Medical Sciences, Philadelphia College of Osteopathic Medicine, Philadelphia, PA, USA.
Zitieren
APA
Chen, J., Chen, Q., Wang, Z., Yan, X., Wang, Y., Zhang, Y., Zhang, J., Xu, J., Ma, Q., Zhong, P., Zhang, D., Liu, Q., Lan, W., & Jiang, J. (2024). Establishing a model predicting Gleason grade group upgrading in prostate cancer. Translational Andrology and Urology, 13(8), 1378-1387. https://doi.org/10.21037/tau-24-155
Vancouver
Chen J, Chen Q, Wang Z, Yan X, Wang Y, Zhang Y, et al. Establishing a model predicting Gleason grade group upgrading in prostate cancer. Translational Andrology and Urology. 2024;13(8):1378-1387. doi:10.21037/tau-24-155
BibTeX
@article{Chen2024,
author = {Chen, Jian and Chen, Qiming and Wang, Ze and Yan, Xuzhi and Wang, Yapeng and Zhang, Yao and Zhang, Jun and Xu, Jing and Ma, Qiang and Zhong, Peng and Zhang, Dianzheng and Liu, Qiuli and Lan, Weihua and Jiang, Jun},
title = {Establishing a model predicting Gleason grade group upgrading in prostate cancer},
journal = {Translational Andrology and Urology},
year = {2024},
volume = {13},
number = {8},
pages = {1378--1387},
doi = {10.21037/tau-24-155}
}
EUVIMED